APA (7th ed.) Citation

E, N., T, Y., H, M., N, Y., CF, C., YS, L., . . . K, Y. (2024). A phase 3 study (PATHWAY) of palbociclib plus tamoxifen in patients with HR-positive/HER2-negative advanced breast cancer. NPJ breast cancer, 10(1), 76. https://doi.org/10.1038/s41523-024-00684-w

Chicago Style (17th ed.) Citation

E, Noguchi, et al. "A Phase 3 Study (PATHWAY) of Palbociclib Plus Tamoxifen in Patients with HR-positive/HER2-negative Advanced Breast Cancer." NPJ Breast Cancer 10, no. 1 (2024): 76. https://doi.org/10.1038/s41523-024-00684-w.

MLA (9th ed.) Citation

E, Noguchi, et al. "A Phase 3 Study (PATHWAY) of Palbociclib Plus Tamoxifen in Patients with HR-positive/HER2-negative Advanced Breast Cancer." NPJ Breast Cancer, vol. 10, no. 1, 2024, p. 76, https://doi.org/10.1038/s41523-024-00684-w.